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MAJOR ARTICLE

Dihydrofolate Reductase Mutations in Plasmodium
vivax from Indonesia and Therapeutic Response
to Sulfadoxine plus Pyrimethamine
Michele D. Hastings,1 Kathryn M. Porter,1 Jason D. Maguire,2 Ika Susanti,2 Winni Kania,2 Michael J. Bangs,2
Carol Hopkins Sibley,1 and J. Kevin Baird2,a
1

Department of Genome Sciences, School of Medicine, University of Washington, Seattle; 2Parasitic Diseases Program, United States Naval
Medical Research Unit 2, Jakarta, Indonesia

Background. The target enzyme of pyrimethamine is dihydrofolate reductase (DHFR), but little is known about
allelic variants of dhfr in Plasmodium vivax populations. Still less is known about associations between specific alleles
and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocytic stages of P. vivax in vivo.
Methods. We studied P. vivax dhfr mutations in 24 patients who received S/P therapy in Papua or Central
Java, Indonesia, and we measured the resistance of the alleles in vitro in a dhfr yeast expression assay.
Results. Fourteen (58%) of 24 patients had an inadequate therapeutic response. Two of 6 alleles that were
identified were novel. One allele that expressed 4 point mutations (57L+58R+61M+117T) correlated with a high
risk of therapeutic failure. The 9 patients infected by P. vivax carrying this allele proved 23 times more likely to
experience early therapeutic failure, compared with patients infected by P. vivax carrying other alleles (P p .003;
95% confidence interval, 2–450). This allele also conferred high levels of pyrimethamine resistance in vitro. The
experimental antifolate WR99210 inhibited the allele in this system.
Conclusions. The present study identified a strong correlation between specific mutations in P. vivax dhfr and
S/P treatment failure. Our results suggest that WR99210 could provide effective therapy for S/P-resistant P. vivax.
Plasmodium vivax infects an estimated 80 million people each year, causing severe and debilitating febrile
illness. The risk of infection by this parasite is increasing
in areas of endemicity, and the geographic range of risk
has expanded rapidly during the past 10 years [1, 2].
Resistance to widely available and applied therapies,
such as chloroquine, may substantially contribute to
this problem [3]. Fansidar, a fixed combination of sul-
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fadoxine and pyrimethamine (S/P), is not recommended
for therapy of P. vivax malaria (vivax malaria) [4], on
the basis of its historically poor demonstrated efficacy
[5–9]. However, in areas of endemicity, S/P is widely
used to treat chloroquine-resistant malaria caused by
Plasmodium falciparum. Where these species occur together, P. vivax may often be treated with S/P, either
because of mixed infection, inaccurate diagnosis, or
economic issues. The risk of therapeutic failure associated with the use of S/P for P. vivax affects strategies
for malaria-treatment policies. Molecular probes that
reliably predict susceptibility of P. vivax to S/P would
provide information supporting rational policy decisions and practice with regard to malaria treatment.
S/P resistance in P. vivax also poses important questions with regard to the development of new antimalarial drugs. Drugs that are effective against both P.
falciparum and P. vivax offer obvious advantages in
areas where these infections occur together—notably,
in southern Asia and South America. The most conspicuous advantage is that appropriate therapy would
not hinge on an accurate diagnosis of the parasite species. The dihydrofolate reductase (DHFR; E.C. 1.5.1.3)
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enzyme of plasmodia is the therapeutic target of the pyrimethamine component of S/P [10]. Extensive laboratory and field
studies of P. falciparum have demonstrated that resistance to
pyrimethamine is caused by dhfr alleles that carry specific point
mutations [11–17]. In P. falciparum, clinical resistance to S/P
apparently requires an accumulation of ⭓3 mutations in dhfr
[18], and the resistance is augmented by additional mutations
in dihydropteroate synthase, the target of sulfadoxine [19–21].
DHFR in P. vivax has not been evaluated as thoroughly as that
in P. falciparum, but mutant alleles are prevalent in Southeast
Asia [7, 22–27], and mutations at positions 57, 58, and 117
have been associated with antifolate resistance [7, 26]. One
study suggested that parasites that carry the wild-type dhfr allele
are susceptible to S/P, as are parasites with alleles that contain
1 or 2 mutations [7]. WR99210 is a novel antifolate drug with
potent activity against S/P-resistant P. falciparum [28], and analogues of WR99210 currently are in the preclinical phase of
development. If drugs of this class exert similar activity against
S/P-resistant P. vivax, this finding would greatly increase their
potential clinical usefulness [29, 30]
The dhfr gene from P. falciparum can be expressed in yeast
that lack endogenous DHFR activity. These engineered yeast
lines exhibit in vitro susceptibility to antifolate drugs that reflects the susceptibility of the parasite from which the dhfr allele
was isolated [31, 32]. We have previously used this assay system
to evaluate several alleles of P. vivax dhfr for susceptibility to
pyrimethamine, chlorcycloguanil, and WR99210 [30]. The P. vivax dhfr alleles evaluated in the present study were cloned and
sequenced from the blood of patients in Indonesia who were
treated with S/P and observed for 28 days. Some alleles were also
generated by site-directed mutagenesis, to assess the relative impact of individual mutations in alleles with multiple mutations.
This approach permitted both assessment of the efficacy of S/P
treatment for P. vivax infections and linkage of in vitro findings
with therapeutic outcomes, thus allowing for a rational assessment of the potential therapeutic efficacy of WR99210 in the
treatment of infection due to S/P-resistant P. vivax.

SUBJECTS, MATERIALS, AND METHODS
Subjects and therapeutic classification. The parasites evaluated in the present study were obtained from a subset of
samples from clinical studies conducted in the Armopa region
of northeastern Papua, Indonesia (from 1996 through 1999),
and in Purworejo in southern Central Java, Indonesia (in 2000).
These studies have been described elsewhere [33, 34]. The parasites evaluated in the present study were obtained from available samples from all subjects who received standard S/P therapy for slide- and polymerase chain reaction (PCR)–proven P.
vivax infection. S/P therapy was not indicated for vivax malaria
in these studies, but the subjects received it as a result of either

an error in initial diagnosis by microscopic examination or the
therapeutic precedence of mixed infection with P. falciparum,
according to study protocol.
Subjects in the clinical studies were followed, by microscopic
examination, for 28 days (with such examinations performed
on days 0–4, 7, 11, 14, 18, 21, and 28, or on any day when
subjects were ill), after they received directly observed S/P therapy (single dose: [25 mg sulfadoxine + 1.25 mg pyrimethamine]/kg body weight). We classified therapeutic outcomes as
(1) “susceptible,” if parasitemia cleared by day 4 and did not
reappear by day 28; (2) “responsive,” if parasitemia cleared by
day 4 but reappeared between days 8 and 28; and (3) “resistant,”
if parasitemia either failed to clear by day 4 or cleared but then
reappeared by day 7. Susceptible and resistant classifications
represented firm, but not entirely unambiguous, characterizations of the therapeutic response to S/P. Rapid clearance of
parasitemia and failure of parasitemia to reappear by day 28
were consistent with a susceptible response, but they did not
preclude the possibility of recrudescence (as subpatent parasitemia) beyond day 28. Failure of parasitemia to clear by day 4
or reappearance of parasitemia by day 7 was consistent with
therapeutic failure but did not preclude emergence of parasitemia caused by reinfection or relapse in subjects exposed to
continuous risk of infection. Infections classified as responsive
were considered to be either moderately, but not completely,
susceptible to S/P or confounded by reinfection and relapse.
Cloning and sequencing of DHFR. Genomic P. vivax DNA
was extracted from dried blood blots on filter paper, by use of
the blood blot DNA extraction protocol from a commercial kit
(QIAamp DNA Mini Kit; Qiagen). The dhfr gene was then
amplified by PCR in a 100-mL reaction, with 2 mL of Taq polymerase (Promega), 10 mL of 10⫻ PCR buffer, 8 mL of 25 mmol/
L MgCl2, 1 mL of 10 mmol/L each primer, 1 mL of 10 mmol/L
each dNTP, 10 mL of template DNA, and 67 mL of PCR H20.
The primers used were as described elsewhere [30]. The 5 end
of each primer is complementary to the sequence of the shuttle
plasmid at the desired insertion position, to facilitate homologous recombination in yeast [35, 36]. The cycling parameters
were as follows: (1) initial denaturation at 94C for 3 min,
followed by 5 cycles of denaturation at 94C for 1 min, elongation at 60C for 1 min, and extension at 72C for 1 min; (2)
5 cycles of denaturation at 94C for 1 min, elongation at 55C
for 1 min, and extension at 72C for 1 min; and (3) 20 cycles
of denaturation at 94C for 1 min, elongation at 55C for 1
min, and extension at 72C for 1 min.
The Saccharomyces cerevisiae yeast strain that was used lacks
endogenous DHFR activity and has been described elsewhere
[30, 32]. Yeast were transformed using a high-efficiency lithium
acetate protocol [37]; they then were plated onto medium that
lacked tryptophan, to select for the plasmid, and that also lacked
deoxythymidine monophosphate, to select for functional DHFR
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activity. Escherichia coli strain DH5a was used for propagation
and preparation of the shuttle plasmid from the transformed
yeast. The plasmid was isolated and purified from the bacteria
by use of a commercial kit (QIAprep Spin Miniprep Kit; Qiagen).
Sequencing was conducted by fluorescent dye chemical analysis
(MegaBACE; Amersham Pharmacia Biotech), and sequences
were analyzed using Sequencher software (Gene Codes). At least
4 isolates from each patient sample were sequenced to check for
mixed genotypes; if the 4 isolates were not all in agreement, then
an additional 4–7 isolates were sequenced to verify the mixed
genotype. Site-directed mutagenesis (QuikChange; Stratagene)
was used to engineer mutations into the wild-type dhfr sequence,
for generating alleles not found in the patient samples.
The work with human subjects in this study was reviewed
(protocols DoD #30820 and DoD #30839) and approved by
US Navy and Indonesian institutional review boards. All subjects provided written informed consent to participate in the
study, in accordance with US Navy regulations governing the
use of human subjects for medical research (SECNAVINST
3900.39C).
In vitro susceptibility classification. The IC50 assays were
performed as described elsewhere [38], to obtain quantitative
measures of drug susceptibility. The growth of the yeast in this
assay depends on the antifolate resistance of the dhfr allele
expressed. In the present study, an “IC50” is defined as the
concentration of drug at which the growth of the yeast culture
is inhibited by 50% relative to that of the untreated control.
Yeast transformed with dhfr from P. vivax were grown overnight
in a 96-well culture dish in complete medium (yeast extract,
peptone, and dextrose [YEPD] broth) lacking dTMP. The
growth of the yeast in each well was assessed by spectrophotometry after incubation at 30C for ∼24 h, which is the amount
of time required for the untreated control yeast to reach midlog phase. The average reading for each allele at each drug
concentration was then used to plot the percent growth relative
to that of the control. The numerical IC50 value was calculated
from the slope and the intercept of the line defined by the 2
data points that bracket 50% relative growth. Comparisons of
the IC50 values of the mutant alleles with those of the wildtype allele were used to assess the relative drug-resistance level
of each allele. IC50 assays were performed at least twice for each
allele, to determine the SD and to ensure reproducibility.
Assessment of the therapeutic risk of DHFR mutations.
The odds ratio (OR) for therapeutic failure, relative to the dhfr
allele, was calculated by standard x 2 analyses. We report 95%
confidence intervals (CIs) for the OR and a P value calculated
by 2-tailed Fisher’s exact test, by use of EpiInfo software, version
7.0. (public domain software; US Centers for Disease Control
and Prevention). P ! .05, along with a 95% CI that excludes
1.0, was considered to be consistent with an association between
an allele and therapeutic outcome.
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RESULTS
Parasitologic response to S/P. The primary goal was to classify the therapeutic response to S/P treatment for infections
with P. vivax. Table 1 classifies the responses of the 24 subjects
evaluated. Ten subjects exhibited responses that were consistent
with S/P susceptibility, 5 subjects had recurrent parasitemia that
was classified as responsive, and 9 subjects had S/P-resistant
infections.
dhfr Alleles. Six alleles, including wild-type alleles, were
isolated from the samples collected immediately before S/P
therapy was administered (table 1). Five (21%) of the 24 patient samples contained P. vivax with mixed dhfr genotypes,
indicating a polyclonal infection. Three of the alleles (58R+
117N+99S, 58R+117N+199V, and 57L+58R+61M+117T) are
novel for this species or have only very recently been described.
The presence of 99S and 199V mutations has not been previously reported. The 2 most prevalent alleles in this sample
were 58R+117N and 57L+58R+61M+117T; these alleles account for 22 of the 29 alleles (13 of the alleles were 58R+117N,
and 9 were 57L+58R+61M+117T). The wild-type allele was
found only once, whereas the 58R, 58R+117N+199V, and
58R+117N+99S alleles were each observed twice. The doublemutant allele isolated from sample UW16 had an additional
silent mutation (GGTrGGC) at codon 101; this was the only
silent change that was observed. We observed 3 different codons
that all encoded the arginine amino-acid change at position 58.
The AGCrAGA mutation was present in all 58R single-mutant
alleles and 58R+117N+199V triple-mutant alleles, as well as in
1 double-mutant allele found in a mixed sample with a
58R+117N+199V allele (UW19). The double-mutant allele isolated from sample UW14 carried an AGCrCGC mutation at
codon 58. All 58R+117N+99S and 57L+58R+61M+117T alleles
shared the AGCrAGG mutation at position 58.
dhfr Alleles and clinical response to S/P. Table 1 lists the
dhfr genotype(s) and therapeutic response of each isolate evaluated. Of the 9 patients with parasites that contained quadruplemutant dhfr alleles, 7 showed responses consistent with S/P resistance, whereas the remaining 2 showed responses that were
fully susceptible. Of the infections associated with the 15 isolates
with only wild-type, single, double, or triple mutations in dhfr,
only 2 infections showed therapeutic responses that were consistent with resistance to S/P. Of parasites from 9 infections
that were classified as resistant, 7 carried the quadruple mutation. Three of 5 parasites classified as being responsive to
treatment carried either a triple- or quadruple-mutant allele,
and only 3 of 10 classified as susceptible carried either a tripleor quadruple-mutant allele. Parasites that carried highly mutant
alleles of dhfr appeared to be more resistant to S/P treatment.
Table 2 compares the risk of therapeutic failure when parasites
carry the quadruple-mutant allele relative to the risk of therapeutic failure when parasites carry any other allele. Polyclonal

Table 1. The dhfr genotypes of and therapeutic responses for
24 patients from Papua and Central Java, Indonesia, who received
therapy with sulfadoxine/pyrimethamine for Plasmodium vivax
infection.
No. of
clones
Patient Location sequenced

Genotypesa

Therapeutic
responseb

UW06

Papua

11

Wild type

Susceptible

UW24

Java

10

58R+117N+99S and
58R+117N

Susceptible

UW05

Papua

4

58R+117N

Susceptible

UW12

Papua

5

58R+117N

Susceptible

UW13

Papua

4

58R+117N

Susceptible

UW18

Papua

4

58R+117N

Susceptible

UW20

Papua

10

58R+117N

Susceptible

UW27

Java

5

58R+117N

Susceptible

UW07

Papua

7

57L+58R+61M+117T Susceptible

UW23

Papua

4

57L+58R+61M+117T Susceptible

UW25

Java

5

58R+117N+99S

UW19

Papua

10

58R+117N+199V and Responsive
58R+117N

UW10

Papua

13

58R+117N

Responsive

UW11

Papua

4

58R+117N

Responsive

UW17

Papua

8

58R+117N

Responsive

UW02

Papua

8

58R+117N+199V
and 58R

Resistant

UW14

Papua

5

58R+117N

Resistant

UW16

Papua

10

57L+58R+61M+117T Resistant
and 58R+117N

UW01

Papua

10

57L+58R+61M+117T Resistant
and 58R

UW03

Papua

11

57L+58R+61M+117T Resistant

UW04

Papua

9

57L+58R+61M+117T Resistant

UW08

Papua

4

57L+58R+61M+117T Resistant

UW09

Papua

5

57L+58R+61M+117T Resistant

UW15

Papua

5

57L+58R+61M+117T Resistant

Responsive

a

Mixed genotypes resulted from polyclonal infection. The codon position
of each mutation and the amino acid encoded by the mutation are given;
standard amino-acid abbreviations are used.
b
“Resistant” denotes either failure of parasitemia to clear by day 4 or
clearance of parasitemia by day 4, followed by reappearance by day 7; “responsive” denotes clearance of parasitemia by day 4, followed by reappearance between days 8 and 28; and “susceptible” denotes clearance of parasitemia by day 4 and no reappearance of parasitemia by day 28.

infections were classified according to the most highly mutated
dhfr allele present. Patients with the quadruple-mutant allele
were 23 times more likely to show a poor therapeutic response,
compared with patients with other dhfr alleles (table 2; P p
.003; 95% CI, 2–450). Similarly, when polyclonal infections
were excluded from analysis, patients with the quadruplemutant allele were 25 times more likely to show a poor therapeutic response (P ! .01; 95% CI, 2–347).
Yeast expression system susceptibility. Susceptibility of P.

vivax to antifolates cannot be easily assayed in vitro. We created,
as a surrogate, a series of yeast lines that each depend on a
different vivax dhfr allele to assess relative in vitro levels of
sensitivity to pyrimethamine and the experimental DHFR inhibitor WR99210. Table 3 presents the mean IC50 values (
SD) for pyrimethamine and WR99210, in addition to the ratio
of resistance, compared with that of the wild type, for each
mutant allele.
The yeast line expressing the quadruple-mutant allele 57L+
58R+61M+117T did not demonstrate any significant inhibition
of growth at drug concentrations of up to 500 mmol/L pyrimethamine. Therefore, the enzyme encoded by this quadruplemutant allele is 1500 times more resistant to pyrimethamine
than is the wild type. To investigate whether the novel 61M
mutation contributes to this high level of resistance, we constructed the triple-mutant allele 57L+58R+117T (which lacks
the 61M mutation) by use of site-directed mutagenesis. This
allele was significantly less resistant than the quadruple-mutant
allele (270-fold vs. 1500-fold). We also constructed alleles with
the 58R+117T mutations and the 117T mutation alone. Both
showed relatively modest resistance to pyrimethamine (40–43fold greater than resistance of the wild type).
The 117T allele conferred slight (1.6-fold) resistance to
WR99210, whereas the 58R+117T double-mutant allele conferred a 10-fold increase in resistance to WR99210. The addition of the 57L mutation to create the 57L+58R+117T allele
decreased resistance to WR99210 (5-fold more than the wild
type). Finally, the quadruple-mutant allele 57L+58R+61M+
117T, which is essentially insensitive to pyrimethamine in this
system, showed an ∼90-fold increased level of resistance to
WR99210, compared with the wild type.
We determined the in vitro sensitivities to pyrimethamine
and WR99210 of the novel triple-mutant alleles (58R+117N+
99S and 58R+117N+199V), relative to those of the doublemutant allele (58R+117N). All 3 alleles show high levels of
resistance to pyrimethamine, ranging from 80-fold to 240-fold
resistance, compared with the wild type. The addition of the
99S mutation to the 58R+117N allele did not increase resistance
to pyrimethamine, but the addition of the 199V mutation produced an allele with an IC50 value that was more than twice
that of the double mutant. All 3 alleles were more sensitive
to WR99210 than was the wild-type allele (table 3). The 58R
single-mutant allele was slightly more resistant to pyrimethamine (1.3-fold more resistant) than was the wild-type allele
in the yeast system, whereas it was 8.5-fold more resistant to
WR99210 than was the wild type.

DISCUSSION
Six different alleles of dhfr were found in this sample of 24
isolates of P. vivax from Indonesia. Subjects infected by parasites
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Table 2. Risk analysis for the genotype and therapeutic response of each isolate associated with infection, including
mixed-genotype infections, in 15 patients.
b

Therapeutic response

Susceptible
and/or
Resistant responsive ORc

Genotypea
Quadruple mutant

7

NOTE.

2

Pd

2
23

Single, double, or triple
mutant or wt

95%
CIc

2–450 .003

13

CI, confidence interval; OR, odds ratio; wt, wild type.

a

The genotype classification is assigned according to the most highly mutated allele in the sample.
b
“Resistant” denotes either failure of parasitemia to clear by day 4 or
clearance of parasitemia by day 4, followed by reappearance by day 7; “responsive” denotes clearance of parasitemia by day 4, followed by reappearance between days 8 and 28; and “susceptible” denotes clearance of parasitemia by day 4 and no reappearance of parasitemia by day 28.
c
Calculated by standard x2 analysis.
d
Calculated by Fisher’s exact test.

that carried the quadruple-mutant allele 57R+58L+61M+117T
were 23 times more likely to experience therapeutic failure,
compared with subjects infected by parasites that carried only
wild-type, single-, double-, or triple-mutant alleles of dhfr. Two
subjects infected by parasites that carried the quadruple-mutant
allele had a good therapeutic response, and this may reflect the
operation of host factors (e.g., immunity) as contributing determinants of therapeutic outcomes. Of the 15 subjects who
carried only parasites with wild-type, single, double, or triple
mutations in dhfr, only 2 showed therapeutic responses that were
consistent with resistance. Those exceptional outcomes could be
the result of one of any number of explanations, such as poor
absorption of drug or efficient use of exogenous folate by the
parasites. In addition, like most studies evaluating the efficacy of
drugs against P. vivax, accurate designation of clinical outcomes
as treatment failures was limited by the possibility of early relapse
and reinfection in evaluated cases. The trends detected in our
sample nonetheless point to dhfr genotype in P. vivax as a probable determinant of therapeutic outcome with S/P.
The poor therapeutic response to S/P by P. vivax was documented in early studies [5, 9]. S/P is not recommended for
treatment of vivax malaria [4]. Recent studies in Thailand,
which demonstrated clinical efficacy of just 40% and 31%,
corroborate that view [6, 7]. An intervention employing mass
administration of S/P and primaquine in northern Sumatra,
Indonesia, sharply reduced falciparum malaria but not vivax
malaria [8]. Although such findings are often attributed to an
inherent tolerance of pyrimethamine by P. vivax [5, 9], recent
studies point to dhfr mutations as the more likely explanation
[7, 26]. This is an important point that bears directly on approaches to discovery of drugs for the treatment of vivax malaria. If the molecular basis of poor therapeutic response is
748 • JID 2004:189 (15 February) • Hastings et al.

understood, it may be addressed in drug design and in vitro
assessment. This was the rationale behind our assessment of
dhfr alleles in a yeast expression system allowing relative measures of DHFR inhibition by antifolates.
The in vitro yeast expression assay system made it possible
to dissect the contributions of specific mutations to DHFR
inhibition and, presumably, therapeutic outcome. We detected
58R alleles in parasites from 2 clinically resistant infections
mixed with triple- or quadruple-mutant alleles and, thus, could
not assess the role of the 58R mutation in that therapeutic
outcome. However, the 58R mutation had a negligible effect
on pyrimethamine sensitivity in the yeast system. The 99S mutation did not confer additional resistance to pyrimethamine,
compared with that conferred by the double-mutant allele
58R+117N. This finding is consistent with the fact that the
mutation occurred in a region that is prone to insertion and
deletion events [22, 27] (M.D.H., unpublished data) and, apparently, is located peripheral to the folate-binding pocket of
the enzyme (C.H.S., unpublished data). In contrast, the in vitro analyses revealed that the 61M mutation is an important
contributing factor to DHFR inhibition by pyrimethamine:
57L+58R+117T showed 270-fold resistance, whereas 57L+58R+
61M+117T showed 1500-fold resistance.
The in vitro analyses of the inhibition of dhfr mutants by
WR99210 point to a high probability of therapeutic efficacy
against S/P-susceptible and -resistant P. vivax. The poor therapeutic response of P. vivax to S/P is evidently linked to the
quadruple-mutant allele of the dhfr gene, and these data, along
with the data from several recent studies, suggest that this quadruple-mutant allele may be widespread in Southeast Asia [26,
27]. The quadruple-mutant allele also showed the highest level
of in vitro resistance to WR99210, relative to the other 5 alleles.
However, the IC50 value for this allele was only 92 times greater than the IC50 value measured for the wild type, whereas
no other allele was 110-fold more resistant than the wild type.
S/P was still clinically effective against parasites carrying alleles
that were 80–240-fold more resistant to pyrimethamine than
was the wild type. If this ratio of effectiveness is also observed
for drugs of the WR99210 class, even parasites that carry the
quadruple-mutant allele might be successfully treated with a
drug of this kind. As development of these drugs proceeds,
testing their effectiveness against strains of P. vivax that are
highly resistant to pyrimethamine should be a high priority.
The clinical findings reported in the present study provide
a benchmark for correlation with findings of the in vitro yeast
expression assay [30]. The in vitro inhibition of expressed
DHFR mutants correlated well with the clinical outcomes of
parasite populations carrying the corresponding alleles. For
example, the dhfr double-mutant allele 58R+117N was 100fold more resistant to pyrimethamine than the was wild-type
allele in the in vitro assay, and the triple-mutant allele 58R+

Table 3. Plasmodium vivax dhfr alleles and IC50 values measured in the yeast
expression system.
IC50  SD, mmol/L
dhfr Allelea

Impact of mutation on IC50

Pyrimethamine

WR99210

Wild type

1.0  0.3

0.58  .08

117T

41  2

0.91  .06

40

58R+117T

44  2

6.0  1.4

43

270  10

2.9  1.3

1500

54  16

57L+58R+117T
57L+58R+61M+117T
58R

1.4  0.8

4.9  3.0

58R+117N

110  28

0.26  .02

84  5.5

58R+117N+99S
58R+117N+199V

250  11

Pyrimethamine
1.0

260
1500

1.3

b

WR99210
1.0
1.6
10
5.0
92
8.5

100

0.44

0.41  .04

81

0.70

0.44  .003

240

0.76

a

The codon position of each mutation and the amino acid encoded by the mutation are given;
standard amino-acid abbreviations are used.
b
Fold wild-type IC50 value.

117N+99S had a similar resistance level; clinical isolates that
carried these alleles were generally susceptible or responsive
to S/P treatment. In contrast, the quadruple mutant was 1500
times more resistant to pyrimethamine in yeast and exhibited
very poor clinical response to S/P treatment. These data will
allow an estimation of the in vivo S/P susceptibility of P. vivax
parasites that carry a novel allele of dhfr, by determining the
relative level of pyrimethamine resistance in the yeast expression system.
As in other studies using sequence analysis of dhfr, in the
present study, we detected novel alleles [26, 27]. The diversity
of mutations in dhfr is apparently rich in natural parasite populations, and allele-specific methods do not reveal this diversity.
For example, position 117 of P. vivax dhfr corresponds to position 108 in the P. falciparum enzyme. In P. falciparum, highly
pyrimethamine-resistant alleles carry an asparagine at this position. Therefore, the frequent finding of the threonine mutation in the P. vivax isolates evaluated in the present study
was quite unexpected. An allele-specific PCR protocol was initially used to characterize P. vivax dhfr alleles in Thailand, on
the basis of a P. falciparum model, under the assumption that
triple mutants that did not carry the wild-type serine at position
117 had a mutation to asparagine [7]. When the entire coding
sequence was determined, it was found that these alleles, in
fact, carried a threonine at position 117 [27]. This difference
emphasizes the importance of direct sequence analysis of P.
vivax dhfr, because P. vivax has greater allelic diversity than is
found in P. falciparum.
In summary, of the 6 different alleles that were detected in
24 patient samples from Papua and Central Java, Indonesia,
only the quadruple-mutant allele was linked to a high risk of
therapeutic failure of S/P. The yeast in vitro expression system
allowed us to examine, in detail, the response of the various
alleles to both S/P and WR99210, and there was a strong cor-

relation between the therapeutic response to S/P and the susceptibility of yeast lines carrying the various alleles. The in vitro system also allowed us to predict that the experimental
DHFR inhibitor, WR99210, is likely to demonstrate good clinical efficacy against P. vivax parasites carrying the S/P-resistant
quadruple mutant reported in the present study. Furthermore,
WR99210 may be particularly effective against parasites carrying the double- and triple-mutant alleles. The effectiveness
of WR99210 against the alleles of P. falciparum dhfr that are
most resistant to pyrimethamine is well established [31, 39],
and extending that effectiveness to treatment of P. vivax infections is an exciting possibility [29].
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